Severe Immune Checkpoint Inhibitor-associated Gastritis Treated with Steroids and Infliximab.
This case report describes a 77-year-old man with severe immune-related gastritis after receiving pembrolizumab for lung cancer.
APA
Tanaka K, Morisawa T, et al. (2026). Severe Immune Checkpoint Inhibitor-associated Gastritis Treated with Steroids and Infliximab.. Internal medicine (Tokyo, Japan), 65(8), 1138-1142. https://doi.org/10.2169/internalmedicine.5736-25
MLA
Tanaka K, et al.. "Severe Immune Checkpoint Inhibitor-associated Gastritis Treated with Steroids and Infliximab.." Internal medicine (Tokyo, Japan), vol. 65, no. 8, 2026, pp. 1138-1142.
PMID
40967796
Abstract
This case report describes a 77-year-old man with severe immune-related gastritis after receiving pembrolizumab for lung cancer. Despite initial steroid therapy, he showed no improvement and was diagnosed with steroid refractory immune-related gastritis. Infliximab was added to steroid therapy, resulting in significant clinical and endoscopic improvement. This highlights the importance of early diagnosis of immune-related gastritis by endoscopic and histological findings. Prompt evaluation of steroid efficacy and the early use of infliximab in steroid refractory cases are emphasized for effective management of immune-related gastritis as the indications for immune checkpoint inhibitors have expanded.
MeSH Terms
Humans; Aged; Male; Infliximab; Gastritis; Immune Checkpoint Inhibitors; Antibodies, Monoclonal, Humanized; Lung Neoplasms; Treatment Outcome; Steroids; Drug Therapy, Combination
같은 제1저자의 인용 많은 논문 (5)
- Reduced-Dose Bendamustine as a First-Line Treatment of Follicular Lymphoma Is Associated With Poorer Prognosis.
- Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab.
- Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017.
- Clinical Utility of a Prognostic Scoring System Based on LDH and CRP in HCC Patients Receiving Atezolizumab Plus Bevacizumab.
- Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin-Based Tumor Marker Score for First-Line Immunotherapy Selection in Hepatocellular Carcinoma.